Beyond KIT in CBF-AML: Chromatin and Cohesin

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2016 May 22

PMID 27207321

Citations 6

Authors

Rachel E Rau

Affiliations

Soon will be listed here.

Citing Articles

Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world.

Zhai Y, Wang Q, Ji L, Ren H, Dong Y, Yang F Cancer Med. 2023; 12(24):21592-21604.

PMID: 38062912 PMC: 10757144. DOI: 10.1002/cam4.6693.

A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment.

Tseng S, Lee M, Lin P Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004478 PMC: 10674205. DOI: 10.3390/ph16111614.

Research progress on molecular biomarkers of acute myeloid leukemia.

Yin P, Wang R, Jing R, Li X, Ma J, Li K Front Oncol. 2023; 13:1078556.

PMID: 36824144 PMC: 9941555. DOI: 10.3389/fonc.2023.1078556.

Natural HDAC-1/8 inhibitor baicalein exerts therapeutic effect in CBF-AML.

Yu X, Li H, Hu P, Qing Y, Wang X, Zhu M Clin Transl Med. 2020; 10(4):e154.

PMID: 32898337 PMC: 7449246. DOI: 10.1002/ctm2.154.

Core binding factor acute myeloid leukemia: Advances in the heterogeneity of , , and mutations (Review).

Quan X, Deng J Mol Clin Oncol. 2020; 13(2):95-100.

PMID: 32714530 PMC: 7366242. DOI: 10.3892/mco.2020.2052.

References

Lavallee V, Lemieux S, Boucher G, Gendron P, Boivin I, Armstrong R . RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. Blood. 2016; 127(20):2498-501. DOI: 10.1182/blood-2016-03-703868. View

Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S . Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016; 127(20):2451-9. PMC: 5457131. DOI: 10.1182/blood-2015-12-688705. View

Ley T, Miller C, Ding L, Raphael B, Mungall A, Robertson A . Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22):2059-74. PMC: 3767041. DOI: 10.1056/NEJMoa1301689. View

Mazumdar C, Shen Y, Xavy S, Zhao F, Reinisch A, Li R . Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. Cell Stem Cell. 2015; 17(6):675-688. PMC: 4671831. DOI: 10.1016/j.stem.2015.09.017. View

Metzeler K . ASXL genes and RUNX1: an intimate connection?. Blood. 2014; 124(9):1382-3. PMC: 4148754. DOI: 10.1182/blood-2014-07-586073. View

Luskin M, Lee J, Fernandez H, Abdel-Wahab O, Bennett J, Ketterling R . Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016; 127(12):1551-8. PMC: 4807422. DOI: 10.1182/blood-2015-07-657403. View

Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P . Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013; 121(12):2213-23. DOI: 10.1182/blood-2012-10-462879. View

Speck N, Gilliland D . Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002; 2(7):502-13. DOI: 10.1038/nrc840. View

Sood R, Hansen N, Donovan F, Carrington B, Bucci D, Maskeri B . Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia. Leukemia. 2015; 30(2):501-4. PMC: 4679720. DOI: 10.1038/leu.2015.141. View

10.

Micol J, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O . Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood. 2014; 124(9):1445-9. PMC: 4148766. DOI: 10.1182/blood-2014-04-571018. View